RCKT241018C35000
- 0.10
- 0.000.00%
Rocket Pharmaceuticals Newsroom
Rocket Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $38
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $38 to $53
Rocket Pharmaceuticals Price Target Maintained With a $52.00/Share by Needham
Rocket Pharmaceuticals Analyst Ratings
Buy Rating for Rocket Pharmaceuticals Amid Positive Projections for RP-A501 Danon Disease Study
Rocket Pharmaceuticals (RCKT) Receives a Buy From Bank of America Securities
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Zymeworks (ZYME) and Rocket Pharmaceuticals (RCKT)
Solid Clinical Progress and Strong Financial Position Reinforce Buy Rating for Rocket Pharmaceuticals
LifeSci Capital Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $53
Buy Rating Affirmed on Rocket Pharmaceuticals Amid Promising Gene Therapy Advances and Solid Financials
Morgan Stanley Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $45 to $65
Rocket Pharmaceuticals Price Target Maintained With a $62.00/Share by Chardan Capital
Analysts' Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM), Rocket Pharmaceuticals (RCKT) and BioNTech SE (BNTX)
Rocket Pharmaceuticals Analyst Ratings
Rocket Pharmaceuticals (RCKT) Gets a Buy From TD Cowen
Rocket Pharmaceuticals Analyst Ratings
Rocket Pharmaceuticals Analyst Ratings
Analysts' Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)